Company Announcement / Press release Archives - Page 21 of 22

Xspray Pharma’s HyNap-Dasa Shows Formal Bioequivalence

STOCKHOLM, SWEDEN – October 10, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) can today present data confirming formal bioequivalence for the company’s lead product candidate, HyNap-Dasa, compared to Sprycel® (dasatinib). ”It has taken us three years of work to come to these encouraging results and the excitement in the company is clearly present today. We […]

Ribbskottet AB increases its stake in Xspray Pharma

STOCKHOLM – September 24, 2018. Xspray Pharma (Nasdaq First North: XSPRAY) (“Xspray”) has received information that Ribbskottet AB has purchased a total of 223,000 shares in the company from Recipharm Venture Fund AB. The transfer took place outside the stock exchange. Ribbskottet’s holding in Xspray now amounts to 10 percent of the number of shares […]

Xspray Pharma announces positive clinical data for its lead product candidate HyNap-Dasa

STOCKHOLM – September 9, 2018. Xspray Pharma AB (Nasdaq First North: XSPRAY) today announces positive data from a clinical bioequivalence study with the company’s lead product candidate HyNap-Dasa. The study results confirmed its primary aim to show bioequivalence of an optimized formulation of HyNap-Dasa compared to Sprycel®. The data will be instrumental in the design […]

Xspray Pharma and NerPharMa deliver clinical trial material to HyNap-Dasa study

Today, Xspray Pharma reported that the first clinical trial material from NerPharMa S.r.l., Xspray’s strategic pharmaceutical manufacturing partner in Milan, has been delivered to the HyNap-Dasa clinical trial, the results of which are expected in Q3 2018. HyNap-Dasa is one of three product candidates that Xspray currently has in development. The company’s goal is to […]

Xspray Pharma gets go-ahead from the Swedish MPA for clinical study

Xspray Pharma has obtained approval from the Swedish Medical Products Agency (MPA) to carry out a previously announced clinical study of the formulation of the company’s product candidate HyNap-Dasa. The study is part of Xspray’s clinical program and will be completed during the third quarter. The objective is to confirm the bioequivalence of the optimized […]

Xspray Pharma Chariman divests 4,000 shares to cover Danish capital gains tax on unrealised gains on Xspray Pharma shares

Xspray Pharma’s Chairman, Michael Wolff Jensen’s private, fully owned holding company MWJ Partners ApS has sold 4,000 shares in Xspray Pharma. The proceeds cover incurred Danish capital gains tax, which is charged on unrealized capital gains on MWJ Partners’ holding of shares in Xspray Pharma. After the transaction, Michael Wolff Jensen holds 31,864 shares and […]

Notice of annual general meeting in Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ), reg. no. 556649-3671 are hereby summoned to attend the annual general meeting ("AGM") on Monday, 14 May, 2018, at 11.00 a.m. CET at IVA Konferenscenter’s premises on Grev Turegatan 16 in Stockholm, Sweden. Right to participate Those who have been recorded as shareholders in the share register kept […]

Bulletin from the extraordinary general meeting of Xspray Pharma AB (publ)

On 20 February, 2018, Xspray Pharma AB (publ) held an extraordinary general meeting. The following resolution, among others, were passed at the general meeting. Directed issue of shares The general meeting resolved, in accordance with the board of directors’ proposal, to carry out a directed issue of not more than 1,350,000 new shares, entailing an […]

Notice of extraordinary general meeting in Xspray Pharma AB (publ)

The shareholders of Xspray Pharma AB (publ) are hereby summoned to attend the extraordinary general meeting (“EGM”) on Tuesday, 20 February, 2018, at 11.00 CET at Advokatfirman Vinge’s offices on Smålandsgatan 20 in Stockholm, Sweden. Right to participate Those who have been recorded as shareholders in the share register kept by Euroclear Sweden AB as […]

Xspray Pharma proposes a directed issue of 1,350,000 shares corresponding to approximately SEK 88 million to expand the product portfolio

The board of directors of Xspray Pharma AB (publ) has resolved to propose a directed share issue of 1,350,000 shares at a subscription price of SEK 65 per share, representing a discount of 2 percent compared to the volume weighted average price during the last five trading days. The share issue will provide Xspray Pharma […]